Design and challenges of the Randomized Evaluation of Normal versus augmented level replacement therapy (RENAL) trial: High-dose versus standard-dose hemofiltration in acute renal failure
Rinaldo Bellomo, Alan Cass, Louise Cole, Simon Finfer, Martin Gallagher, Donna Goldsmith, John Myburgh, Robyn Norton, Carlos Scheinkestel
Blood Purification | KARGER | Published : 2008
BACKGROUND/AIMS: The optimal dose of renal replacement therapy (RRT) in acute renal failure (ARF) is uncertain. METHODS: The Randomized Evaluation of Normal versus Augmented Level Replacement Therapy Trial tests the hypothesis that higher dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 40 ml/kg/h will increase survival compared to CVVHDF at 25 ml/kg/h of effluent dose. RESULTS: This trial is currently randomizing critically ill patients in 35 intensive care units in Australia and New Zealand with a planned sample size of 1,500 patients. This trial will be the largest trial ever conducted on acute blood purification in critically ill patients. CONCLUSION: A trial..View full abstract
Awarded by National Health and Medical Research Council of Australia
The study was funded by grant No. 352550 from the National Health and Medical Research Council of Australia and by a grant from the Health Research Council of New Zealand.